AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
MorningStar·
- AstraZeneca announced that its breast-cancer pill Etcamah, combined with Pfizer's Ibrance, missed the primary goal of statistically significant disease progression delay in a late-stage trial.
- Despite this trial setback, the FDA recently approved the drug for advanced breast cancer with a specific mutation based on separate trial results.
- Additionally, AstraZeneca and Daiichi Sankyo reported that their Enhertu drug showed significant benefits in a late-stage advanced lung cancer study.
